| Ticker | Value |
|---|---|
| ASI | 249,712.33 |
| Deals | 62386 |
| Volume | 711862568 |
| Value | ₦29,084,008,003.67 |
| Equity Cap | ₦160,077,253,377.13 |
| Ticker | Prev. Close | Price | Change |
|---|---|---|---|
FGSUK2031S4 | ₦81.00 | ₦98.99 | 22.21% |
JAPAULGOLD | ₦3.72 | ₦4.09 | 9.95% |
ZICHIS | ₦29.13 | ₦32.04 | 9.99% |
ABCTRANS | ₦7.51 | ₦8.26 | 9.99% |
LIVINGTRUST | ₦3.83 | ₦4.21 | 9.92% |
Posted on: 2026-02-10
May & Baker Nigeria Plc has delivered an exceptional financial performance for the full year 2025, unveiling unaudited results that paint a robust picture of growth and efficiency. This significant turnaround, particularly its impressive profit before tax of N6.55 billion – a staggering increase from N2.57 billion in 2024 – is set to bolster confidence among Nigerian investors and potentially reshape perceptions of the pharmaceutical giant's trajectory.
The company's strong showing was evident across the board, with the fourth quarter alone witnessing a remarkable swing from a pre-tax loss of N168.46 million in Q4 2024 to a substantial N1.64 billion profit before tax in Q4 2025. This decisive year-on-year improvement signals effective strategic adjustments and operational optimization.
This surge in profitability is excellent news for current and prospective Nigerian investors. An increase in profit before tax typically translates to higher earnings per share (EPS), which directly impacts shareholder returns. Indeed, May & Baker's EPS rose significantly to N2.58 from N0.93, indicating a more profitable enterprise and potentially a more attractive dividend payout in the future. Improved profitability also often correlates with share price appreciation, offering capital gains for investors.
The underlying drivers of this stellar performance are clear and strategically sound:
Robust Pharmaceutical Sales: The pharmaceutical segment remains the bedrock of May & Baker's success, contributing an overwhelming N37.77 billion (98.72%) to the total revenue of N38.26 billion (a 32.38% increase year-on-year from N28.9 billion). This highlights the company's strong market position and demand for its pharmaceutical products within Nigeria.
Operational Efficiency: Gross profit saw a remarkable 54.4% jump to N13.14 billion from N8.51 billion, indicating improved cost of goods sold management despite increased sales. Critically, the company managed to trim administrative expenses to N2.6 billion from N2.8 billion, showcasing disciplined cost control.
Doubled Operating Profit: As a direct result of strong sales and reduced expenses, operating profit more than doubled to N6.53 billion from N2.56 billion, reflecting superior operational efficiency.
Healthy Interest Income: While finance costs increased to N673.13 million, this was largely mitigated by a substantial rise in interest income to N711.57 million (from N407.49 million), driven by higher bank interest. This suggests effective cash management and benefiting from the prevailing interest rate environment.
Strong Bottom-Line: Consequently, both Profit Before Tax (N6.55 billion) and Profit After Tax (N4.45 billion) saw significant increases from N2.57 billion and N1.62 billion respectively in 2024.
The company's balance sheet also reflects this newfound strength, a reassuring factor for Nigerian investors focused on long-term stability:
Asset Expansion: Total assets grew to N25.61 billion from N22.45 billion, with healthy contributions from cash and cash equivalents (N6.5 billion) and property, plant, and equipment (N6.3 billion). This indicates a growing asset base to support future operations.
Equity Growth: Total equity swelled to N13.6 billion from N9.8 billion, primarily fueled by increased retained earnings, which hit N9.3 billion (up from N5.6 billion). This organic growth in equity strengthens the company's financial foundation.
Reduced Obligations: Notably, total obligations declined to N11.9 billion from N12.5 billion, with borrowings narrowing to N3.3 billion from N3.5 billion. A reduction in debt generally signifies improved financial health and lower risk for shareholders.
In essence, May & Baker Nigeria Plc's 2025 results present a compelling narrative of strategic success. For Nigerian investors, this performance signals a company that has effectively navigated economic headwinds, demonstrated robust operational efficiency, and is now poised for sustainable growth, potentially offering enhanced returns and a more secure investment proposition.
